Skip to main content
CEL SCI CORP logo

CEL SCI CORP — Investor Relations & Filings

Ticker · CVM ISIN · US1508377066 LEI · 549300FIWOFSETIVMI17 US Professional, scientific and technical activities
Open in API
Filings indexed 1,087 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US CVM

About CEL SCI CORP

https://cel-sci.com/

CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2026
2026-05-15 English
FORM 8-K
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 8-K Current Report under the Securities Exchange Act of 1934, reporting Item 1.01 (Entry into a Material Definitive Agreement). It does not contain full financial statements but is a regulatory disclosure filing. Under the defined taxonomy, an 8-K is classified as a general regulatory announcement (Regulatory Filings, code RNS).
2026-05-14 English
8-K - CEL SCI CORP (0000725363) (Filer)
Capital/Financing Update Classification · 97% confidence The document is a U.S. SEC Form 8-K current report describing the entry into a Placement Agency Agreement and the closing of a 6,000,000 share placement for gross proceeds of $7.2 million. This is a direct update on a corporate fundraising transaction and change in capital structure rather than a full report, legal proceeding, or proxy. It fits the definition of a Capital/Financing Update.
2026-05-13 English
424B4
Share Issue/Capital Change Classification · 81% confidence The document is an EDGAR prospectus (Form S-1/Rule 424(b)(4)) describing the offering of 6,000,000 new shares of common stock at $1.20 per share, detailing the terms of sale, placement agent arrangements, use of proceeds, risk factors, etc. It is a primary share issuance prospectus for fundraising, not an internal report or a short announcement. This fits the definition of a Share Issue/Capital Change filing (SHA).
2026-05-13 English
Regulatory Filings 2026
Regulatory Filings
2026-05-12 English
S-1/A - CEL SCI CORP (0000725363) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is a preliminary prospectus for a securities offering, describing the terms of the offering, the securities to be sold, the use of proceeds, risk factors, and other related information. This type of filing is related to capital raising activities and is not a financial report, earnings release, or management discussion. It is specifically a registration statement amendment for a public offering of securities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, confirming it is a substantive filing about financing.
2026-05-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.